Herbert Kuster

Zurich, ZH, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Rare twin cysteine residues in the HIV-1 envelope variable region 1 link to neutralization escape and breadth development.

Rare twin cysteine residues in the HIV-1 envelope variable region 1 link to neutralization escape and breadth development.

Journal: Cell host & microbe
Published: June 02, 2026

Evaluation of the ELITe InGenius PCR assay compared with immunofluorescence for Pneumocystis jirovecii detection in respiratory samples.

Evaluation of the ELITe InGenius PCR assay compared with immunofluorescence for Pneumocystis jirovecii detection in respiratory samples.

Journal: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
Published: December 10, 2025

Viral and Immune Risk Factors of HIV Rebound After Interruption of Antiretroviral Therapy.

Viral and Immune Risk Factors of HIV Rebound After Interruption of Antiretroviral Therapy.

Journal: The Journal of infectious diseases
Published: September 18, 2024

Rare twin cysteine residues in the HIV-1 envelope variable region 1 link to neutralization escape and breadth development.

Rare twin cysteine residues in the HIV-1 envelope variable region 1 link to neutralization escape and breadth development.

Journal: Cell host & microbe
Published: September 10, 2024

Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks.

Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks.

Journal: The Journal of infectious diseases
Published: May 05, 2023

Sustained Viral Suppression With Dolutegravir Monotherapy Over 192 Weeks in Patients Starting Combination Antiretroviral Therapy During Primary Human Immunodeficiency Virus Infection (EARLY-SIMPLIFIED): A Randomized, Controlled, Multi-site, Noninferiority Trial.

Sustained Viral Suppression With Dolutegravir Monotherapy Over 192 Weeks in Patients Starting Combination Antiretroviral Therapy During Primary Human Immunodeficiency Virus Infection (EARLY-SIMPLIFIED): A Randomized, Controlled, Multi-site, Noninferiority Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: February 10, 2023

The Interplay Between Replication Capacity of HIV-1 and Surrogate Markers of Disease.

The Interplay Between Replication Capacity of HIV-1 and Surrogate Markers of Disease.

Journal: The Journal of infectious diseases
Published: January 05, 2022

Detecting Selection in the HIV-1 Genome during Sexual Transmission Events.

Detecting Selection in the HIV-1 Genome during Sexual Transmission Events.

Journal: Viruses
Published: December 09, 2021

Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials.

Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials.

Journal: Journal of acquired immune deficiency syndromes (1999)
Published: February 17, 2021

A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells.

A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells.

Journal: Viruses
Published: February 03, 2021

HIV-1 integration sites in CD4+ T cells during primary, chronic, and late presentation of HIV-1 infection.

HIV-1 integration sites in CD4+ T cells during primary, chronic, and late presentation of HIV-1 infection.

Journal: JCI insight
Published: September 03, 2020

Noninferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-label, Noninferiority Trial.

Noninferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-label, Noninferiority Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 01, 2018
Showing 1-12 of 23

Last Updated: 09/26/2026